Cytokinetics Inc

Company Profile

Cytokinetics Inc had its IPO on 2004-04-29 under the ticker symbol CYTK.

The company operates in the Healthcare sector and Biotechnology industry. Cytokinetics Inc has a staff strength of 409 employees.

Stock update

Shares of Cytokinetics Inc opened at $34.73 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $34.26 - $35.22, and closed at $35.05.

This is a +0.92% increase from the previous day's closing price.

A total volume of 579,707 shares were traded at the close of the day’s session.

In the last one week, shares of Cytokinetics Inc have slipped by -2.64%.

Cytokinetics Inc's Key Ratios

Cytokinetics Inc has a market cap of $3.63 billion, indicating a price to book ratio of 31.8985 and a price to sales ratio of 27.5151.

In the last 12-months Cytokinetics Inc’s revenue was $98.05 million with a gross profit of $-146225000 and an EBITDA of $-364496992. The EBITDA ratio measures Cytokinetics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cytokinetics Inc’s operating margin was -378.18% while its return on assets stood at -26.55% with a return of equity of -572.15%.

In Q1, Cytokinetics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 301.8%.

Cytokinetics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

-0.42

Its diluted EPS in the last 12-months stands at $-4.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.42. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytokinetics Inc’s profitability.

Cytokinetics Inc stock is trading at a EV to sales ratio of 21.9676 and a EV to EBITDA ratio of -13.9229. Its price to sales ratio in the trailing 12-months stood at 27.5151.

Cytokinetics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$889.82 million

Total Liabilities

$75.22 million

Operating Cash Flow

$165.50 million

Capital Expenditure

$402000

Dividend Payout Ratio

0%

Cytokinetics Inc ended 2024 with $889.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $889.82 million while shareholder equity stood at $-229020000.00.

Cytokinetics Inc ended 2024 with $0 in deferred long-term liabilities, $75.22 million in other current liabilities, 94000.00 in common stock, $-1717283000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $101.62 million and cash and short-term investments were $663.96 million. The company’s total short-term debt was $14,263,000 while long-term debt stood at $64.11 million.

Cytokinetics Inc’s total current assets stands at $680.63 million while long-term investments were $40.41 million and short-term investments were $562.35 million. Its net receivables were $1.01 million compared to accounts payable of $17.36 million and inventory worth $0.

In 2024, Cytokinetics Inc's operating cash flow was $165.50 million while its capital expenditure stood at $402000.

Comparatively, Cytokinetics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$35.05

52-Week High

$55.8

52-Week Low

$32.96

Analyst Target Price

$61.14

Cytokinetics Inc stock is currently trading at $35.05 per share. It touched a 52-week high of $55.8 and a 52-week low of $55.8. Analysts tracking the stock have a 12-month average target price of $61.14.

Its 50-day moving average was $33.67 and 200-day moving average was $37.95 The short ratio stood at 10.26 indicating a short percent outstanding of 0%.

Around 85.2% of the company’s stock are held by insiders while 11510.6% are held by institutions.